skip to main content
Washington State Institute for Public Policy
Back Button

Individual drug counseling approach for the treatment of cocaine addiction

Substance Use Disorders: Treatment for Adults
Benefit-cost methods last updated December 2024.  Literature review updated May 2014.
This program was archived December 2024.
Individual drug counseling for the treatment of cocaine addiction is a manualized treatment that can be provided as a component of comprehensive outpatient therapy or as a standalone treatment. The manualized version was developed for use in the Collaborative Cocaine Treatment Study, where the individual counseling was provided in addition to group counseling. The individual drug counseling approach follows a 12-step philosophy and addresses the physical, emotional, spiritual, and interpersonal needs of the client. The model is generally applied in 36 individual sessions over six months with booster sessions as needed.
 
ALL
BENEFIT-COST
META-ANALYSIS
CITATIONS
For an overview of WSIPP's Benefit-Cost Model, please see this guide. The estimates shown are present value, life cycle benefits and costs. All dollars are expressed in the base year chosen for this analysis (2022).  The chance the benefits exceed the costs are derived from a Monte Carlo risk analysis. The details on this, as well as the economic discount rates and other relevant parameters are described in our 2023 Technical Documentation.
Benefit-Cost Summary Statistics Per Participant
Benefits to:
Taxpayers $744 Benefits minus costs $3,380
Participants $1,067 Benefit to cost ratio $2.21
Others $320 Chance the program will produce
Indirect $4,051 benefits greater than the costs 54%
Total benefits $6,181
Net program cost ($2,802)
Benefits minus cost $3,380

^WSIPP’s benefit-cost model does not monetize this outcome.

Meta-analysis is a statistical method to combine the results from separate studies on a program, policy, or topic to estimate its effect on an outcome. WSIPP systematically evaluates all credible evaluations we can locate on each topic. The outcomes measured are the program impacts measured in the research literature (for example, impacts on crime or educational attainment). Treatment N represents the total number of individuals or units in the treatment group across the included studies.

An effect size (ES) is a standard metric that summarizes the degree to which a program or policy affects a measured outcome. If the effect size is positive, the outcome increases. If the effect size is negative, the outcome decreases. See Estimating Program Effects Using Effect Sizes for additional information on how we estimate effect sizes.

The effect size may be adjusted from the unadjusted effect size estimated in the meta-analysis. Historically, WSIPP adjusted effect sizes to some programs based on the methodological characteristics of the study. For programs reviewed in 2024 or later, we do not make additional adjustments, and we use the unadjusted effect size whenever we run a benefit-cost analysis.

Research shows the magnitude of effects may change over time. For those effect sizes, we estimate outcome-based adjustments, which we apply between the first time ES is estimated and the second time ES is estimated. More details about these adjustments can be found in our 2023 Technical Documentation.

Meta-Analysis of Program Effects
Outcomes measured Treatment age No. of effect sizes Treatment N Effect sizes (ES) and standard errors (SE) used in the benefit-cost analysis Unadjusted effect size (random effects model)
First time ES is estimated Second time ES is estimated
ES SE Age ES SE Age ES p-value
Major depressive disorder
Clinical diagnosis of major depression or symptoms measured on a validated scale.
 45 1 92 -0.093 0.169 45 0.000 0.187 48 -0.093 0.579
Illicit drug use disorder
Clinical diagnosis of illicit drug use disorder or symptoms measured on a validated scale. When possible, we exclude cannabis/marijuana use disorder from this outcome.
 45 1 121 -0.307 0.167 45 0.000 0.187 48 -0.307 0.066
Anxiety disorder
Clinical diagnosis of an anxiety disorder (e.g., general anxiety, panic, social anxiety, obsessive compulsive disorder) or symptoms measured on a validated scale.
 45 1 92 0.044 0.168 45 0.000 0.187 48 0.044 0.793
Alcohol use^
Adult use of alcohol that does not rise to the level of “problem” or “disordered.”
 45 1 92 0.208 0.169 45 n/a n/a n/a 0.208 0.218
Psychiatric symptoms^
Mental health symptoms (such as symptoms of psychosis) in individuals with serious mental illness, measured on a validated scale.
 45 1 92 -0.274 0.169 45 n/a n/a n/a -0.274 0.105
1In addition to the outcomes measured in the meta-analysis table, WSIPP measures benefits and costs estimated from other outcomes associated with those reported in the evaluation literature. For example, empirical research demonstrates that high school graduation leads to reduced crime. These associated measures provide a more complete picture of the detailed costs and benefits of the program.

2“Others” includes benefits to people other than taxpayers and participants. Depending on the program, it could include reductions in crime victimization, the economic benefits from a more educated workforce, and the benefits from employer-paid health insurance.

3“Indirect benefits” includes estimates of the net changes in the value of a statistical life and net changes in the deadweight costs of taxation.
Detailed Monetary Benefit Estimates Per Participant
Affected outcome: Resulting benefits:1 Benefits accrue to:
Taxpayers Participants Others2 Indirect3 Total
Illicit drug use disorder Criminal justice system $0 $0 $0 $0 $0
Labor market earnings associated with illicit drug abuse or dependence $365 $861 $0 $0 $1,226
Health care associated with illicit drug abuse or dependence $317 $49 $326 $159 $851
Mortality associated with illicit drugs $206 $486 $0 $5,296 $5,989
Anxiety disorder Labor market earnings associated with anxiety disorder ($139) ($328) $0 $0 ($467)
Health care associated with anxiety disorder ($6) ($2) ($7) ($3) ($18)
Program cost Adjustment for deadweight cost of program $0 $0 $0 ($1,401) ($1,401)
Totals $744 $1,067 $320 $4,051 $6,181
Click here to see populations selected
Detailed Annual Cost Estimates Per Participant
Annual cost Year dollars Summary
Program costs $2,311 2013 Present value of net program costs (in 2022 dollars) ($2,802)
Comparison costs $0 2013 Cost range (+ or -) 10%
This program is typically delivered over a six-month period. The per-participant cost of treatment is based on the single study in the analysis and includes 36 individual 50-minute sessions estimated using Washington’s Medicaid hourly reimbursement rate for individual treatment. The costs of this intervention are in addition to group therapy provided to both the treated and comparison groups.
The figures shown are estimates of the costs to implement programs in Washington. The comparison group costs reflect either no treatment or treatment as usual, depending on how effect sizes were calculated in the meta-analysis. The cost range reported above reflects potential variation or uncertainty in the cost estimate; more detail can be found in our 2023 Technical Documentation.
Benefits Minus Costs
Benefits by Perspective
Taxpayer Benefits by Source of Value
Benefits Minus Costs Over Time (Cumulative Discounted Dollars)
The graph above illustrates the estimated cumulative net benefits per-participant for the first fifty years beyond the initial investment in the program. We present these cash flows in discounted dollars. If the dollars are negative (bars below $0 line), the cumulative benefits do not outweigh the cost of the program up to that point in time. The program breaks even when the dollars reach $0. At this point, the total benefits to participants, taxpayers, and others, are equal to the cost of the program. If the dollars are above $0, the benefits of the program exceed the initial investment.

Citations Used in the Meta-Analysis

Crits-Christoph, P., Siqueland, L., McCalmont, E., Frank, A., Blaine, J., Weiss, R.D., . . . , Thase, M.E. (2001). Impact of psychosocial treatments on associated problems of cocaine-dependent patients. Journal of Consulting and Clinical Psychology, 69(5), 825-830.

Crits-Christoph, P., Siqueland, L., Blaine, J., Frank, A., Luborsky, L., Onken, L.S., . . . , Beck, A.T. (1999). Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Archives of General Psychiatry, 56(6), 493-502.